TY  - JOUR
AU  - Resanović, Ivana
AU  - Zarić, Božidarka
AU  - Radovanović, Jelena V.
AU  - Sudar-Milovanović, Emina
AU  - Gluvić, Zoran
AU  - Jevremović, Danimir
AU  - Isenović, Esma R.
PY  - 2020
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/9662
AB  - Vascular complications in patients with diabetes mellitus (DM) are common. Since impaired oxygen balance in plasma plays an important role in the pathogenesis of chronic DM-associated complications, the administration of hyperbaric oxygen therapy (HBOT) has been recommended to influence development of vascular complications. Hyperbaric oxygen therapy involves inhalation of 100% oxygen under elevated pressure from 1.6 to 2.8 absolute atmospheres in hyperbaric chambers. Hyperbaric oxygen therapy increases plasma oxygen solubility, contributing to better oxygen diffusion to distant tissues and preservation of the viability of tissues reversibly damaged by atherosclerosis-induced ischemia, along with microcirculation restoration. Hyperbaric oxygen therapy exerts antiatherogenic, antioxidant, and cardioprotective effects by altering the level and composition of plasma fatty acids and also by promoting signal transduction through membranes, which are impaired by hyperglycemia and hypoxia. In addition, HBOT affects molecules involved in the regulation of nitric oxide synthesis and in that way exerts anti-inflammatory and angiogenic effects in patients with DM. In this review, we explore the recent literature related to the effects of HBOT on DM-related vascular complications.
T2  - Angiology
T1  - Hyperbaric Oxygen Therapy and Vascular Complications in Diabetes Mellitus
VL  - 71
IS  - 10
SP  - 876
EP  - 885
DO  - 10.1177/0003319720936925
ER  - 

@article{
author = "Resanović, Ivana and Zarić, Božidarka and Radovanović, Jelena V. and Sudar-Milovanović, Emina and Gluvić, Zoran and Jevremović, Danimir and Isenović, Esma R.",
year = "2020",
abstract = "Vascular complications in patients with diabetes mellitus (DM) are common. Since impaired oxygen balance in plasma plays an important role in the pathogenesis of chronic DM-associated complications, the administration of hyperbaric oxygen therapy (HBOT) has been recommended to influence development of vascular complications. Hyperbaric oxygen therapy involves inhalation of 100% oxygen under elevated pressure from 1.6 to 2.8 absolute atmospheres in hyperbaric chambers. Hyperbaric oxygen therapy increases plasma oxygen solubility, contributing to better oxygen diffusion to distant tissues and preservation of the viability of tissues reversibly damaged by atherosclerosis-induced ischemia, along with microcirculation restoration. Hyperbaric oxygen therapy exerts antiatherogenic, antioxidant, and cardioprotective effects by altering the level and composition of plasma fatty acids and also by promoting signal transduction through membranes, which are impaired by hyperglycemia and hypoxia. In addition, HBOT affects molecules involved in the regulation of nitric oxide synthesis and in that way exerts anti-inflammatory and angiogenic effects in patients with DM. In this review, we explore the recent literature related to the effects of HBOT on DM-related vascular complications.",
journal = "Angiology",
title = "Hyperbaric Oxygen Therapy and Vascular Complications in Diabetes Mellitus",
volume = "71",
number = "10",
pages = "876-885",
doi = "10.1177/0003319720936925"
}

Resanović, I., Zarić, B., Radovanović, J. V., Sudar-Milovanović, E., Gluvić, Z., Jevremović, D.,& Isenović, E. R.. (2020). Hyperbaric Oxygen Therapy and Vascular Complications in Diabetes Mellitus. in Angiology, 71(10), 876-885.
https://doi.org/10.1177/0003319720936925

Resanović I, Zarić B, Radovanović JV, Sudar-Milovanović E, Gluvić Z, Jevremović D, Isenović ER. Hyperbaric Oxygen Therapy and Vascular Complications in Diabetes Mellitus. in Angiology. 2020;71(10):876-885.
doi:10.1177/0003319720936925 .

Resanović, Ivana, Zarić, Božidarka, Radovanović, Jelena V., Sudar-Milovanović, Emina, Gluvić, Zoran, Jevremović, Danimir, Isenović, Esma R., "Hyperbaric Oxygen Therapy and Vascular Complications in Diabetes Mellitus" in Angiology, 71, no. 10 (2020):876-885,
https://doi.org/10.1177/0003319720936925 . .

TY  - JOUR
AU  - Resanović, Ivana
AU  - Gluvić, Zoran
AU  - Zarić, Božidarka
AU  - Sudar-Milovanović, Emina
AU  - Vučić, Vesna
AU  - Arsić, Aleksandra
AU  - Nedić, Olgica
AU  - Šunderić, Miloš
AU  - Gligorijević, Nikola
AU  - Milačić, Davorka
AU  - Isenović, Esma R.
PY  - 2020
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/8567
AB  - Objective: Metabolic changes in insulin-dependent diabetes mellitus (IDDM) impair vasodilation, and this leads to tissue hypoxia and microvascular pathology. Hyperbaric oxygen therapy (HBOT) can significantly improve the outcome of ischemic conditions in IDDM patients and reduce vascular complications. The aim of our study was to assess the effects of HBOT on plasma fatty acid (FA) composition, and expression of insulin-like growth factor binding protein 1 (IGFBP-1) in IDDM patients. Methods: Our study included 24 adult IDDM patients diagnosed with peripheral vascular complications. The patients were exposed to 10 sessions of 100% oxygen inhalation at 2.4 atmosphere absolute for 1 hour. Blood samples were collected at admission and after HBOT for measurement of metabolic parameters, FA composition and IGFBP-1. Measurement of plasma FA composition was determined by gas chromatography. Expression of IGFBP-1 in the serum was estimated by Western blot analysis. Results: HBOT decreased blood levels of total cholesterol (p<0.05), triglycerides (p<0.05) and low-density lipoprotein (p<0.05). HBOT increased plasma levels of individual FAs: palmitic acid (p<0.05), palmitoleic acid (p<0.05), docosapentaenoic acid (p<0.05) and docosahexaenoic acid (p<0.01), and decreased levels of stearic acid (p<0.05), alpha linolenic acid (p<0.05) and linoleic acid (p<0.01). Expression of IGFBP-1 (p<0.01) was increased, whereas the level of insulin (p<0.001) was decreased in the serum after HBOT. Conclusions: Our results indicate that HBOT exerts beneficial effects in IDDM patients by improving the lipid profile and altering FA composition. © 2019 Canadian Diabetes Association
T2  - Canadian Journal of Diabetes
T1  - Effect of Hyperbaric Oxygen Therapy on Fatty Acid Composition and Insulin-like Growth Factor Binding Protein 1 in Adult Type 1 Diabetes Mellitus Patients: A Pilot Study
VL  - 44
IS  - 1
SP  - 22
EP  - 29
DO  - 10.1016/j.jcjd.2019.04.018
ER  - 

@article{
author = "Resanović, Ivana and Gluvić, Zoran and Zarić, Božidarka and Sudar-Milovanović, Emina and Vučić, Vesna and Arsić, Aleksandra and Nedić, Olgica and Šunderić, Miloš and Gligorijević, Nikola and Milačić, Davorka and Isenović, Esma R.",
year = "2020",
abstract = "Objective: Metabolic changes in insulin-dependent diabetes mellitus (IDDM) impair vasodilation, and this leads to tissue hypoxia and microvascular pathology. Hyperbaric oxygen therapy (HBOT) can significantly improve the outcome of ischemic conditions in IDDM patients and reduce vascular complications. The aim of our study was to assess the effects of HBOT on plasma fatty acid (FA) composition, and expression of insulin-like growth factor binding protein 1 (IGFBP-1) in IDDM patients. Methods: Our study included 24 adult IDDM patients diagnosed with peripheral vascular complications. The patients were exposed to 10 sessions of 100% oxygen inhalation at 2.4 atmosphere absolute for 1 hour. Blood samples were collected at admission and after HBOT for measurement of metabolic parameters, FA composition and IGFBP-1. Measurement of plasma FA composition was determined by gas chromatography. Expression of IGFBP-1 in the serum was estimated by Western blot analysis. Results: HBOT decreased blood levels of total cholesterol (p<0.05), triglycerides (p<0.05) and low-density lipoprotein (p<0.05). HBOT increased plasma levels of individual FAs: palmitic acid (p<0.05), palmitoleic acid (p<0.05), docosapentaenoic acid (p<0.05) and docosahexaenoic acid (p<0.01), and decreased levels of stearic acid (p<0.05), alpha linolenic acid (p<0.05) and linoleic acid (p<0.01). Expression of IGFBP-1 (p<0.01) was increased, whereas the level of insulin (p<0.001) was decreased in the serum after HBOT. Conclusions: Our results indicate that HBOT exerts beneficial effects in IDDM patients by improving the lipid profile and altering FA composition. © 2019 Canadian Diabetes Association",
journal = "Canadian Journal of Diabetes",
title = "Effect of Hyperbaric Oxygen Therapy on Fatty Acid Composition and Insulin-like Growth Factor Binding Protein 1 in Adult Type 1 Diabetes Mellitus Patients: A Pilot Study",
volume = "44",
number = "1",
pages = "22-29",
doi = "10.1016/j.jcjd.2019.04.018"
}

Resanović, I., Gluvić, Z., Zarić, B., Sudar-Milovanović, E., Vučić, V., Arsić, A., Nedić, O., Šunderić, M., Gligorijević, N., Milačić, D.,& Isenović, E. R.. (2020). Effect of Hyperbaric Oxygen Therapy on Fatty Acid Composition and Insulin-like Growth Factor Binding Protein 1 in Adult Type 1 Diabetes Mellitus Patients: A Pilot Study. in Canadian Journal of Diabetes, 44(1), 22-29.
https://doi.org/10.1016/j.jcjd.2019.04.018

Resanović I, Gluvić Z, Zarić B, Sudar-Milovanović E, Vučić V, Arsić A, Nedić O, Šunderić M, Gligorijević N, Milačić D, Isenović ER. Effect of Hyperbaric Oxygen Therapy on Fatty Acid Composition and Insulin-like Growth Factor Binding Protein 1 in Adult Type 1 Diabetes Mellitus Patients: A Pilot Study. in Canadian Journal of Diabetes. 2020;44(1):22-29.
doi:10.1016/j.jcjd.2019.04.018 .

Resanović, Ivana, Gluvić, Zoran, Zarić, Božidarka, Sudar-Milovanović, Emina, Vučić, Vesna, Arsić, Aleksandra, Nedić, Olgica, Šunderić, Miloš, Gligorijević, Nikola, Milačić, Davorka, Isenović, Esma R., "Effect of Hyperbaric Oxygen Therapy on Fatty Acid Composition and Insulin-like Growth Factor Binding Protein 1 in Adult Type 1 Diabetes Mellitus Patients: A Pilot Study" in Canadian Journal of Diabetes, 44, no. 1 (2020):22-29,
https://doi.org/10.1016/j.jcjd.2019.04.018 . .

TY  - JOUR
AU  - Resanović, Ivana
AU  - Gluvić, Zoran
AU  - Zarić, Božidarka
AU  - Sudar-Milovanović, Emina
AU  - Jovanović, Aleksandra
AU  - Milačić, Davorka
AU  - Isaković, Radmilo
AU  - Isenović, Esma R.
PY  - 2019
UR  - https://www.hindawi.com/journals/ije/2019/2328505/
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/8209
AB  - This study aimed at examining the early effects of hyperbaric oxygen therapy (HBOT) on inducible nitric oxide synthase (iNOS) activity/expression in lymphocytes of type 1 diabetes mellitus (T1DM) patients. A group of 19 patients (mean age: 63 ± 2.1) with T1DM and with the peripheral arterial disease were included in this study. Patients were exposed to 10 sessions of HBOT in the duration of 1 h to 100% oxygen inhalation at 2.4 ATA. Blood samples were collected for the plasma C-reactive protein (CRP), plasma free fatty acid (FFA), serum nitrite/nitrate, and serum arginase activity measurements. Expression of iNOS and phosphorylation of p65 subunit of nuclear factor- κ B (NF κ B-p65), extracellular-regulated kinases 1/2 (ERK1/2), and protein kinase B (Akt) were examined in lymphocyte lysates by Western blot. After exposure to HBOT, plasma CRP and FFA were significantly decreased ( p < 0.001 ). Protein expression of iNOS and serum nitrite/nitrate levels were decreased ( p < 0.01 ), while serum arginase activity was increased ( p < 0.05 ) versus before exposure to HBOT. Increased phosphorylation of NF κ B-p65 at Ser 536 ( p < 0.05 ) and decreased level of NF κ B-p65 protein ( p < 0.001 ) in lymphocytes of T1DM patients were observed after HBOT. Decreased phosphorylation of ERK1/2 ( p < 0.05 ) and Akt ( p < 0.05 ) was detected after HBOT. Our results indicate that exposure to HBO decreased iNOS activity/expression via decreasing phosphorylation of ERK1/2 and Akt followed by decreased activity of NF κ B.
T2  - International Journal of Endocrinology
T1  - Early Effects of Hyperbaric Oxygen on Inducible Nitric Oxide Synthase Activity/Expression in Lymphocytes of Type 1 Diabetes Patients: A Prospective Pilot Study
VL  - 2019
SP  - 1
EP  - 12
DO  - 10.1155/2019/2328505
ER  - 

@article{
author = "Resanović, Ivana and Gluvić, Zoran and Zarić, Božidarka and Sudar-Milovanović, Emina and Jovanović, Aleksandra and Milačić, Davorka and Isaković, Radmilo and Isenović, Esma R.",
year = "2019",
abstract = "This study aimed at examining the early effects of hyperbaric oxygen therapy (HBOT) on inducible nitric oxide synthase (iNOS) activity/expression in lymphocytes of type 1 diabetes mellitus (T1DM) patients. A group of 19 patients (mean age: 63 ± 2.1) with T1DM and with the peripheral arterial disease were included in this study. Patients were exposed to 10 sessions of HBOT in the duration of 1 h to 100% oxygen inhalation at 2.4 ATA. Blood samples were collected for the plasma C-reactive protein (CRP), plasma free fatty acid (FFA), serum nitrite/nitrate, and serum arginase activity measurements. Expression of iNOS and phosphorylation of p65 subunit of nuclear factor- κ B (NF κ B-p65), extracellular-regulated kinases 1/2 (ERK1/2), and protein kinase B (Akt) were examined in lymphocyte lysates by Western blot. After exposure to HBOT, plasma CRP and FFA were significantly decreased ( p < 0.001 ). Protein expression of iNOS and serum nitrite/nitrate levels were decreased ( p < 0.01 ), while serum arginase activity was increased ( p < 0.05 ) versus before exposure to HBOT. Increased phosphorylation of NF κ B-p65 at Ser 536 ( p < 0.05 ) and decreased level of NF κ B-p65 protein ( p < 0.001 ) in lymphocytes of T1DM patients were observed after HBOT. Decreased phosphorylation of ERK1/2 ( p < 0.05 ) and Akt ( p < 0.05 ) was detected after HBOT. Our results indicate that exposure to HBO decreased iNOS activity/expression via decreasing phosphorylation of ERK1/2 and Akt followed by decreased activity of NF κ B.",
journal = "International Journal of Endocrinology",
title = "Early Effects of Hyperbaric Oxygen on Inducible Nitric Oxide Synthase Activity/Expression in Lymphocytes of Type 1 Diabetes Patients: A Prospective Pilot Study",
volume = "2019",
pages = "1-12",
doi = "10.1155/2019/2328505"
}

Resanović, I., Gluvić, Z., Zarić, B., Sudar-Milovanović, E., Jovanović, A., Milačić, D., Isaković, R.,& Isenović, E. R.. (2019). Early Effects of Hyperbaric Oxygen on Inducible Nitric Oxide Synthase Activity/Expression in Lymphocytes of Type 1 Diabetes Patients: A Prospective Pilot Study. in International Journal of Endocrinology, 2019, 1-12.
https://doi.org/10.1155/2019/2328505

Resanović I, Gluvić Z, Zarić B, Sudar-Milovanović E, Jovanović A, Milačić D, Isaković R, Isenović ER. Early Effects of Hyperbaric Oxygen on Inducible Nitric Oxide Synthase Activity/Expression in Lymphocytes of Type 1 Diabetes Patients: A Prospective Pilot Study. in International Journal of Endocrinology. 2019;2019:1-12.
doi:10.1155/2019/2328505 .

Resanović, Ivana, Gluvić, Zoran, Zarić, Božidarka, Sudar-Milovanović, Emina, Jovanović, Aleksandra, Milačić, Davorka, Isaković, Radmilo, Isenović, Esma R., "Early Effects of Hyperbaric Oxygen on Inducible Nitric Oxide Synthase Activity/Expression in Lymphocytes of Type 1 Diabetes Patients: A Prospective Pilot Study" in International Journal of Endocrinology, 2019 (2019):1-12,
https://doi.org/10.1155/2019/2328505 . .

TY  - JOUR
AU  - Perović, Milan
AU  - Sudar-Milovanović, Emina
AU  - Simonović, Ema D.
AU  - Resanović, Ivana
AU  - Draganić, Veselin D.
AU  - Radaković, Jovana D.
AU  - Soldatović, Ivan A.
AU  - Isenović, Esma R.
PY  - 2019
UR  - https://linkinghub.elsevier.com/retrieve/pii/S0306987718310892
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/8006
AB  - Controlled ovarian stimulation (COS) is used to augment the number of retrieved oocytes in in vitro fertilization (IVF). Follicular fluid (FF) contributes significantly to oocyte quality. Since the FF is composed of follicular secretions and plasma exudation, it reflects alterations in granulosa and thecal cells secretion as well as changes in the level of plasma constituents. Phospholipids (PL) and free fatty acids (FFA) are important constituents of both, FF and serum. Our hypothesis is that COS affects the level of PL and FFA in serum. Furthermore, since the level of PL and FFA in FF partially depends on their levels in serum, as a collaterally of our hypothesis is that the existing level of PL and FFA in serum correlates with the levels of PL and FFA in FF, and that the dose of applied gonadotropins during COS will correlate with the levels of PL and FFA in serum and FF. In addition, we assume that the level of PL and FFA in serum and in FF after COS will correlate with the retrieved number of GQ oocytes, one of the most important outcomes of COS.. © 2018
T2  - Medical Hypotheses
T1  - Hypothesis regarding the effects of gonadotropins on the level of free fatty acids and phospholipids in serum and follicular fluid during controlled ovarian stimulation
VL  - 123
SP  - 30
EP  - 34
DO  - 10.1016/j.mehy.2018.11.021
ER  - 

@article{
author = "Perović, Milan and Sudar-Milovanović, Emina and Simonović, Ema D. and Resanović, Ivana and Draganić, Veselin D. and Radaković, Jovana D. and Soldatović, Ivan A. and Isenović, Esma R.",
year = "2019",
abstract = "Controlled ovarian stimulation (COS) is used to augment the number of retrieved oocytes in in vitro fertilization (IVF). Follicular fluid (FF) contributes significantly to oocyte quality. Since the FF is composed of follicular secretions and plasma exudation, it reflects alterations in granulosa and thecal cells secretion as well as changes in the level of plasma constituents. Phospholipids (PL) and free fatty acids (FFA) are important constituents of both, FF and serum. Our hypothesis is that COS affects the level of PL and FFA in serum. Furthermore, since the level of PL and FFA in FF partially depends on their levels in serum, as a collaterally of our hypothesis is that the existing level of PL and FFA in serum correlates with the levels of PL and FFA in FF, and that the dose of applied gonadotropins during COS will correlate with the levels of PL and FFA in serum and FF. In addition, we assume that the level of PL and FFA in serum and in FF after COS will correlate with the retrieved number of GQ oocytes, one of the most important outcomes of COS.. © 2018",
journal = "Medical Hypotheses",
title = "Hypothesis regarding the effects of gonadotropins on the level of free fatty acids and phospholipids in serum and follicular fluid during controlled ovarian stimulation",
volume = "123",
pages = "30-34",
doi = "10.1016/j.mehy.2018.11.021"
}

Perović, M., Sudar-Milovanović, E., Simonović, E. D., Resanović, I., Draganić, V. D., Radaković, J. D., Soldatović, I. A.,& Isenović, E. R.. (2019). Hypothesis regarding the effects of gonadotropins on the level of free fatty acids and phospholipids in serum and follicular fluid during controlled ovarian stimulation. in Medical Hypotheses, 123, 30-34.
https://doi.org/10.1016/j.mehy.2018.11.021

Perović M, Sudar-Milovanović E, Simonović ED, Resanović I, Draganić VD, Radaković JD, Soldatović IA, Isenović ER. Hypothesis regarding the effects of gonadotropins on the level of free fatty acids and phospholipids in serum and follicular fluid during controlled ovarian stimulation. in Medical Hypotheses. 2019;123:30-34.
doi:10.1016/j.mehy.2018.11.021 .

Perović, Milan, Sudar-Milovanović, Emina, Simonović, Ema D., Resanović, Ivana, Draganić, Veselin D., Radaković, Jovana D., Soldatović, Ivan A., Isenović, Esma R., "Hypothesis regarding the effects of gonadotropins on the level of free fatty acids and phospholipids in serum and follicular fluid during controlled ovarian stimulation" in Medical Hypotheses, 123 (2019):30-34,
https://doi.org/10.1016/j.mehy.2018.11.021 . .

TY  - JOUR
AU  - Kovačević, Pejka
AU  - Gluvić, Zoran
AU  - Putniković, Biljana
AU  - Zarić, Božidarka
AU  - Radenković, Saša
AU  - Resanović, Ivana
AU  - Isenović, Esma R.
PY  - 2018
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/10155
AB  - This study aims to examine the influence of admission glycaemia and glycosylated haemoglobin (HbA1C) levels on the length of hospitalization and its outcome in insulin-independent diabetes mellitus (DM) patients suffering from ST-Segment Elevation Myocardial Infarction (STEMI)/Non-STEMI (NSTEMI). This cross-sectional study included 103 subjects with a history of insulin-independent DM, currently hospitalized due to acute myocardial infarction (AMI). Out of 103 subjects, 59 (57%) were men and 66 (64.1%) of them suffered from STEMI. Mean age of study population was 67±9 years. The following parameters were monitored: demographic, coronary, cardiovascular and DM risk factors history, as well as laboratory, clinical, echocardiography and angiography parameters. DM mean duration was 7 (1-30) months, and it influenced the length of hospitalization (r=0.232, p<0.05), but not the outcome (r=0.174, p>0.05). Mean length of hospitalization was 8 and 8.5 days in STEMI and NSTEMI patients respectively, with no difference between groups (log-rank ch2= 0.476, p>0.05). HbA1C values influenced the length of hospitalization (r=0.213, p<0.05), opposite to admission glycaemia (r=0.148, p>0.05). Duration of DM and the level of HbA1C prolong the length of hospitalization, but do not influence the clinical outcome of AMI patients suffering from insulin-independent DM.
AB  - Cilj prikazane studije je izučavanje uticaja glikemije i glikoziliranog hemoglobina (HbA1C) pri prijemu u bolnicu na dužinu trajanja hospitalizacije, kao i njen ishod kod kod obolelih od insulin-nezavisnog dijabetesa sa NSTEMI/STEMI. Materijal i metode: Ova studija je uključila 103 ispitanika, od kojih su 59 (57%) ispitanici muškog pola, a 66 (64.1%) ispitanika imalo STEMI. Prosečna životna dob ispitivane populacije je bila 67±9 godina. Praćeni su sledeći parametri: demografske karakteristike, anamneza o koronarnim, kardiovaskularnim i rizičnim faktorima za dijabetes, kao i laboratorijski, klinički, ehokardiografski parametri. Rezultati: Prosečno trajanje dijabetesa kod osoba uključenih u studiju je bilo 7 (1-30) meseci i imalo je uticaj na dužinu hospitalizacije (r=0.232, p<0.05), ali ne i na njen krajnji ishod (r=0.174, p>0.05). Prosečno trajanje hospitalizacije je bilo 8 i 8.5 dana kod ispitanika sa STEMI i NSTEMI i nije se razlikovalo među grupama ispitanika (log-rank ch2= 0.476, p>0.05). Nivoi HbA1C su uticali na dužinu trajanja hospitalizacije (r=0.213, p<0.05), što nije bio slučaj sa glikemijom pri prijemu u bolnicu (r=0.148, p>0.05). Zaključak: Dužina trajanja DM i nivo HbA1C produžavaju dužinu hospitalizacije, ali ne utiču na klinički ishod ispitanika sa insulin-nezavisnim dijabetesom koji su doživeli AIM.
T2  - Medicinska istraživanja
T1  - Influence of glycaemia and HbA1C levels at admission of insulin-independent diabetes patients on the length and outcome of hospitalization due to NSTEMI/STEMI
T1  - Uticaj glikemije i nivoa HbA1C na prijemu na dužinu i ishod hospitalizacije kod obolelih od insulin-nezavisnog dijabetesa sa NSTEMI/STEMI
VL  - 52
IS  - 3
SP  - 1
EP  - 6
DO  - 10.5937/MedIst1801001K
ER  - 

@article{
author = "Kovačević, Pejka and Gluvić, Zoran and Putniković, Biljana and Zarić, Božidarka and Radenković, Saša and Resanović, Ivana and Isenović, Esma R.",
year = "2018",
abstract = "This study aims to examine the influence of admission glycaemia and glycosylated haemoglobin (HbA1C) levels on the length of hospitalization and its outcome in insulin-independent diabetes mellitus (DM) patients suffering from ST-Segment Elevation Myocardial Infarction (STEMI)/Non-STEMI (NSTEMI). This cross-sectional study included 103 subjects with a history of insulin-independent DM, currently hospitalized due to acute myocardial infarction (AMI). Out of 103 subjects, 59 (57%) were men and 66 (64.1%) of them suffered from STEMI. Mean age of study population was 67±9 years. The following parameters were monitored: demographic, coronary, cardiovascular and DM risk factors history, as well as laboratory, clinical, echocardiography and angiography parameters. DM mean duration was 7 (1-30) months, and it influenced the length of hospitalization (r=0.232, p<0.05), but not the outcome (r=0.174, p>0.05). Mean length of hospitalization was 8 and 8.5 days in STEMI and NSTEMI patients respectively, with no difference between groups (log-rank ch2= 0.476, p>0.05). HbA1C values influenced the length of hospitalization (r=0.213, p<0.05), opposite to admission glycaemia (r=0.148, p>0.05). Duration of DM and the level of HbA1C prolong the length of hospitalization, but do not influence the clinical outcome of AMI patients suffering from insulin-independent DM., Cilj prikazane studije je izučavanje uticaja glikemije i glikoziliranog hemoglobina (HbA1C) pri prijemu u bolnicu na dužinu trajanja hospitalizacije, kao i njen ishod kod kod obolelih od insulin-nezavisnog dijabetesa sa NSTEMI/STEMI. Materijal i metode: Ova studija je uključila 103 ispitanika, od kojih su 59 (57%) ispitanici muškog pola, a 66 (64.1%) ispitanika imalo STEMI. Prosečna životna dob ispitivane populacije je bila 67±9 godina. Praćeni su sledeći parametri: demografske karakteristike, anamneza o koronarnim, kardiovaskularnim i rizičnim faktorima za dijabetes, kao i laboratorijski, klinički, ehokardiografski parametri. Rezultati: Prosečno trajanje dijabetesa kod osoba uključenih u studiju je bilo 7 (1-30) meseci i imalo je uticaj na dužinu hospitalizacije (r=0.232, p<0.05), ali ne i na njen krajnji ishod (r=0.174, p>0.05). Prosečno trajanje hospitalizacije je bilo 8 i 8.5 dana kod ispitanika sa STEMI i NSTEMI i nije se razlikovalo među grupama ispitanika (log-rank ch2= 0.476, p>0.05). Nivoi HbA1C su uticali na dužinu trajanja hospitalizacije (r=0.213, p<0.05), što nije bio slučaj sa glikemijom pri prijemu u bolnicu (r=0.148, p>0.05). Zaključak: Dužina trajanja DM i nivo HbA1C produžavaju dužinu hospitalizacije, ali ne utiču na klinički ishod ispitanika sa insulin-nezavisnim dijabetesom koji su doživeli AIM.",
journal = "Medicinska istraživanja",
title = "Influence of glycaemia and HbA1C levels at admission of insulin-independent diabetes patients on the length and outcome of hospitalization due to NSTEMI/STEMI, Uticaj glikemije i nivoa HbA1C na prijemu na dužinu i ishod hospitalizacije kod obolelih od insulin-nezavisnog dijabetesa sa NSTEMI/STEMI",
volume = "52",
number = "3",
pages = "1-6",
doi = "10.5937/MedIst1801001K"
}

Kovačević, P., Gluvić, Z., Putniković, B., Zarić, B., Radenković, S., Resanović, I.,& Isenović, E. R.. (2018). Influence of glycaemia and HbA1C levels at admission of insulin-independent diabetes patients on the length and outcome of hospitalization due to NSTEMI/STEMI. in Medicinska istraživanja, 52(3), 1-6.
https://doi.org/10.5937/MedIst1801001K

Kovačević P, Gluvić Z, Putniković B, Zarić B, Radenković S, Resanović I, Isenović ER. Influence of glycaemia and HbA1C levels at admission of insulin-independent diabetes patients on the length and outcome of hospitalization due to NSTEMI/STEMI. in Medicinska istraživanja. 2018;52(3):1-6.
doi:10.5937/MedIst1801001K .

Kovačević, Pejka, Gluvić, Zoran, Putniković, Biljana, Zarić, Božidarka, Radenković, Saša, Resanović, Ivana, Isenović, Esma R., "Influence of glycaemia and HbA1C levels at admission of insulin-independent diabetes patients on the length and outcome of hospitalization due to NSTEMI/STEMI" in Medicinska istraživanja, 52, no. 3 (2018):1-6,
https://doi.org/10.5937/MedIst1801001K . .

TY  - JOUR
AU  - Perović, Milan
AU  - Obradović, Milan M.
AU  - Resanović, Ivana
AU  - Isenović, Esma R.
PY  - 2018
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/7749
T2  - Current Vascular Pharmacology
T1  - Relationship between Vitamin D and Metalloproteinases (MMPs) in Acute Myocardial Infarction (AMI) (Editorial)
VL  - 16
IS  - 4
SP  - 361
EP  - 362
DO  - 10.2174/1570161115999171004111230
ER  - 

@article{
author = "Perović, Milan and Obradović, Milan M. and Resanović, Ivana and Isenović, Esma R.",
year = "2018",
journal = "Current Vascular Pharmacology",
title = "Relationship between Vitamin D and Metalloproteinases (MMPs) in Acute Myocardial Infarction (AMI) (Editorial)",
volume = "16",
number = "4",
pages = "361-362",
doi = "10.2174/1570161115999171004111230"
}

Perović, M., Obradović, M. M., Resanović, I.,& Isenović, E. R.. (2018). Relationship between Vitamin D and Metalloproteinases (MMPs) in Acute Myocardial Infarction (AMI) (Editorial). in Current Vascular Pharmacology, 16(4), 361-362.
https://doi.org/10.2174/1570161115999171004111230

Perović M, Obradović MM, Resanović I, Isenović ER. Relationship between Vitamin D and Metalloproteinases (MMPs) in Acute Myocardial Infarction (AMI) (Editorial). in Current Vascular Pharmacology. 2018;16(4):361-362.
doi:10.2174/1570161115999171004111230 .

Perović, Milan, Obradović, Milan M., Resanović, Ivana, Isenović, Esma R., "Relationship between Vitamin D and Metalloproteinases (MMPs) in Acute Myocardial Infarction (AMI) (Editorial)" in Current Vascular Pharmacology, 16, no. 4 (2018):361-362,
https://doi.org/10.2174/1570161115999171004111230 . .

TY  - CHAP
AU  - Obradović, Milan M.
AU  - Zarić, Božidarka
AU  - Sudar-Milovanović, Emina
AU  - Perović, Milan
AU  - Resanović, Ivana
AU  - Gluvić, Zoran
AU  - Isenović, Esma R.
PY  - 2018
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/8014
AB  - Nitric oxide (NO) is a free radical which, in reactions with various molecules causes multiple biological effects. NO is exceptionally regulated and extends to almost every cell type and function within circulation. Generation and actions of NO are regulated by various hormones under physiological and pathophysiological conditions. Nitric oxide synthases (NOS) are the enzymes responsible for NO generation. In mammals, neuronal NOS (nNOS) and endothelial NOS (eNOS) are constitutively expressed, while inducible NOS (iNOS) mediate in immune defense. Altered NO level is associated with obesity, insulin resistance (IR), diabetes and cardiovascular diseases (CVD). Disturbances in eNOS and iNOS regulation accompany multiple changes in endothelial function and contribute to development of CVD. Furthermore, key step in initiation and progression of atherosclerosis is reduction in bioactivity of endothelial cell-derived NO. Here we shall focus on recent literature data related to the role of eNOS and iNOS in physiological and pathophysiological conditions. © 2018 Nova Science Publishers, Inc. All rights reserved.
PB  - Nova Science Publishers
T2  - Horizons in World Cardiovascular Research
T1  - The role of eNOS and iNOS in pathophysiological conditions
VL  - 15
SP  - 65
EP  - 102
UR  - https://hdl.handle.net/21.15107/rcub_vinar_8014
ER  - 

@inbook{
author = "Obradović, Milan M. and Zarić, Božidarka and Sudar-Milovanović, Emina and Perović, Milan and Resanović, Ivana and Gluvić, Zoran and Isenović, Esma R.",
year = "2018",
abstract = "Nitric oxide (NO) is a free radical which, in reactions with various molecules causes multiple biological effects. NO is exceptionally regulated and extends to almost every cell type and function within circulation. Generation and actions of NO are regulated by various hormones under physiological and pathophysiological conditions. Nitric oxide synthases (NOS) are the enzymes responsible for NO generation. In mammals, neuronal NOS (nNOS) and endothelial NOS (eNOS) are constitutively expressed, while inducible NOS (iNOS) mediate in immune defense. Altered NO level is associated with obesity, insulin resistance (IR), diabetes and cardiovascular diseases (CVD). Disturbances in eNOS and iNOS regulation accompany multiple changes in endothelial function and contribute to development of CVD. Furthermore, key step in initiation and progression of atherosclerosis is reduction in bioactivity of endothelial cell-derived NO. Here we shall focus on recent literature data related to the role of eNOS and iNOS in physiological and pathophysiological conditions. © 2018 Nova Science Publishers, Inc. All rights reserved.",
publisher = "Nova Science Publishers",
journal = "Horizons in World Cardiovascular Research",
booktitle = "The role of eNOS and iNOS in pathophysiological conditions",
volume = "15",
pages = "65-102",
url = "https://hdl.handle.net/21.15107/rcub_vinar_8014"
}

Obradović, M. M., Zarić, B., Sudar-Milovanović, E., Perović, M., Resanović, I., Gluvić, Z.,& Isenović, E. R.. (2018). The role of eNOS and iNOS in pathophysiological conditions. in Horizons in World Cardiovascular Research
Nova Science Publishers., 15, 65-102.
https://hdl.handle.net/21.15107/rcub_vinar_8014

Obradović MM, Zarić B, Sudar-Milovanović E, Perović M, Resanović I, Gluvić Z, Isenović ER. The role of eNOS and iNOS in pathophysiological conditions. in Horizons in World Cardiovascular Research. 2018;15:65-102.
https://hdl.handle.net/21.15107/rcub_vinar_8014 .

Obradović, Milan M., Zarić, Božidarka, Sudar-Milovanović, Emina, Perović, Milan, Resanović, Ivana, Gluvić, Zoran, Isenović, Esma R., "The role of eNOS and iNOS in pathophysiological conditions" in Horizons in World Cardiovascular Research, 15 (2018):65-102,
https://hdl.handle.net/21.15107/rcub_vinar_8014 .

TY  - JOUR
AU  - Gluvić, Zoran
AU  - Zarić, Božidarka
AU  - Resanović, Ivana
AU  - Obradović, Milan M.
AU  - Mitrović, Aleksandar
AU  - Radak, Đorđe J.
AU  - Isenović, Esma R.
PY  - 2017
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/1470
AB  - Metabolic syndrome (MetS) is a leading public health and clinical challenge worldwide. MetS represents a group of interrelated risk factors that predict cardiovascular diseases (CVD) and diabetes mellitus (DM). Its prevalence ranges between 10 and 84%, depending on the geographic region, urban or rural environment, individual demographic characteristics of the population studied (sex, age, racial and ethnic origin), as well as the criteria used to define MetS. Persons with MetS have higher mortality rate when compared with people without MetS, primarily caused by progressive atherosclerosis, accelerated by pro-inflammatory and pro-coagulation components of MetS. Considering the high prevalence of metabolic disorders (glucose metabolism disorder, hypertension, dyslipidaemia, obesity etc.), preventive healthcare should focus on changing lifestyle in order to reduce obesity and increase physical activity. This narrative review considers the available evidence from clinical and experimental studies dealing with MetS, and current treatment options for patients with insulin resistance and MetS.
T2  - Current Vascular Pharmacology
T1  - Link between Metabolic Syndrome and Insulin Resistance
VL  - 15
IS  - 1
SP  - 30
EP  - 39
DO  - 10.2174/1570161114666161007164510
ER  - 

@article{
author = "Gluvić, Zoran and Zarić, Božidarka and Resanović, Ivana and Obradović, Milan M. and Mitrović, Aleksandar and Radak, Đorđe J. and Isenović, Esma R.",
year = "2017",
abstract = "Metabolic syndrome (MetS) is a leading public health and clinical challenge worldwide. MetS represents a group of interrelated risk factors that predict cardiovascular diseases (CVD) and diabetes mellitus (DM). Its prevalence ranges between 10 and 84%, depending on the geographic region, urban or rural environment, individual demographic characteristics of the population studied (sex, age, racial and ethnic origin), as well as the criteria used to define MetS. Persons with MetS have higher mortality rate when compared with people without MetS, primarily caused by progressive atherosclerosis, accelerated by pro-inflammatory and pro-coagulation components of MetS. Considering the high prevalence of metabolic disorders (glucose metabolism disorder, hypertension, dyslipidaemia, obesity etc.), preventive healthcare should focus on changing lifestyle in order to reduce obesity and increase physical activity. This narrative review considers the available evidence from clinical and experimental studies dealing with MetS, and current treatment options for patients with insulin resistance and MetS.",
journal = "Current Vascular Pharmacology",
title = "Link between Metabolic Syndrome and Insulin Resistance",
volume = "15",
number = "1",
pages = "30-39",
doi = "10.2174/1570161114666161007164510"
}

Gluvić, Z., Zarić, B., Resanović, I., Obradović, M. M., Mitrović, A., Radak, Đ. J.,& Isenović, E. R.. (2017). Link between Metabolic Syndrome and Insulin Resistance. in Current Vascular Pharmacology, 15(1), 30-39.
https://doi.org/10.2174/1570161114666161007164510

Gluvić Z, Zarić B, Resanović I, Obradović MM, Mitrović A, Radak ĐJ, Isenović ER. Link between Metabolic Syndrome and Insulin Resistance. in Current Vascular Pharmacology. 2017;15(1):30-39.
doi:10.2174/1570161114666161007164510 .

Gluvić, Zoran, Zarić, Božidarka, Resanović, Ivana, Obradović, Milan M., Mitrović, Aleksandar, Radak, Đorđe J., Isenović, Esma R., "Link between Metabolic Syndrome and Insulin Resistance" in Current Vascular Pharmacology, 15, no. 1 (2017):30-39,
https://doi.org/10.2174/1570161114666161007164510 . .

TY  - JOUR
AU  - Radak, Đorđe J.
AU  - Katsiki, Niki
AU  - Resanović, Ivana
AU  - Jovanović, Aleksandra
AU  - Sudar, Emina
AU  - Zafirović, Sonja
AU  - Mousa, Shaker A.
AU  - Isenović, Esma R.
PY  - 2017
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/1521
AB  - Apoptosis may contribute to a significant proportion of neuron death following acute brain ischemia (ABI), but the underlying mechanisms are still not fully understood. Brain ischemia may lead to stroke, which is one of the main causes of long-term morbidity and mortality in both developed and developing countries. Therefore, stroke prevention and treatment is clinically important. There are two important separate areas of the brain during ABI: the ischemic core and the ischemic penumbra. The ischemic core of the brain experiences a sudden reduction of blood flow, just minutes after ischemic attack with irreversible injury and subsequent cell death. On the other hand, apoptosis within the ischemic penumbra may occur after several hours or days, while necrosis starts in the first hours after the onset of ABI in the ischemic core. ABI is characterized by key molecular events that initiate apoptosis in many cells, such as overproduction of free radicals, Ca2+ overload and excitotoxicity. These changes in cellular homeostasis may trigger either necrosis or apoptosis, which often depends on cell type, cell age, and location in the brain. Apoptosis results in DNA fragmentation, degradation of cytoskeletal and nuclear proteins, cross-linking of proteins, formation of apoptotic bodies, expression of ligands for phagocytic cell receptors and finally uptake by phagocytic cells. This review focuses on recent findings based on animal and human studies regarding the apoptotic mechanisms of neuronal death following ABI and the development of potential neuroprotective agents that reduce morbidity. The effects of statins on stroke prevention and treatment as well as on apoptotic mediators are also considered.
T2  - Current Vascular Pharmacology
T1  - Apoptosis and Acute Brain Ischemia in Ischemic Stroke
VL  - 15
IS  - 2
SP  - 115
EP  - 122
DO  - 10.2174/1570161115666161104095522
ER  - 

@article{
author = "Radak, Đorđe J. and Katsiki, Niki and Resanović, Ivana and Jovanović, Aleksandra and Sudar, Emina and Zafirović, Sonja and Mousa, Shaker A. and Isenović, Esma R.",
year = "2017",
abstract = "Apoptosis may contribute to a significant proportion of neuron death following acute brain ischemia (ABI), but the underlying mechanisms are still not fully understood. Brain ischemia may lead to stroke, which is one of the main causes of long-term morbidity and mortality in both developed and developing countries. Therefore, stroke prevention and treatment is clinically important. There are two important separate areas of the brain during ABI: the ischemic core and the ischemic penumbra. The ischemic core of the brain experiences a sudden reduction of blood flow, just minutes after ischemic attack with irreversible injury and subsequent cell death. On the other hand, apoptosis within the ischemic penumbra may occur after several hours or days, while necrosis starts in the first hours after the onset of ABI in the ischemic core. ABI is characterized by key molecular events that initiate apoptosis in many cells, such as overproduction of free radicals, Ca2+ overload and excitotoxicity. These changes in cellular homeostasis may trigger either necrosis or apoptosis, which often depends on cell type, cell age, and location in the brain. Apoptosis results in DNA fragmentation, degradation of cytoskeletal and nuclear proteins, cross-linking of proteins, formation of apoptotic bodies, expression of ligands for phagocytic cell receptors and finally uptake by phagocytic cells. This review focuses on recent findings based on animal and human studies regarding the apoptotic mechanisms of neuronal death following ABI and the development of potential neuroprotective agents that reduce morbidity. The effects of statins on stroke prevention and treatment as well as on apoptotic mediators are also considered.",
journal = "Current Vascular Pharmacology",
title = "Apoptosis and Acute Brain Ischemia in Ischemic Stroke",
volume = "15",
number = "2",
pages = "115-122",
doi = "10.2174/1570161115666161104095522"
}

Radak, Đ. J., Katsiki, N., Resanović, I., Jovanović, A., Sudar, E., Zafirović, S., Mousa, S. A.,& Isenović, E. R.. (2017). Apoptosis and Acute Brain Ischemia in Ischemic Stroke. in Current Vascular Pharmacology, 15(2), 115-122.
https://doi.org/10.2174/1570161115666161104095522

Radak ĐJ, Katsiki N, Resanović I, Jovanović A, Sudar E, Zafirović S, Mousa SA, Isenović ER. Apoptosis and Acute Brain Ischemia in Ischemic Stroke. in Current Vascular Pharmacology. 2017;15(2):115-122.
doi:10.2174/1570161115666161104095522 .

Radak, Đorđe J., Katsiki, Niki, Resanović, Ivana, Jovanović, Aleksandra, Sudar, Emina, Zafirović, Sonja, Mousa, Shaker A., Isenović, Esma R., "Apoptosis and Acute Brain Ischemia in Ischemic Stroke" in Current Vascular Pharmacology, 15, no. 2 (2017):115-122,
https://doi.org/10.2174/1570161115666161104095522 . .

TY  - JOUR
AU  - Popin-Tarić, Marija
AU  - Gluvić, Zoran
AU  - Mitrović, Bojan
AU  - Samardžić, Vladimir
AU  - Lačković, Milena
AU  - Vasić-Vlaisavljević, Anita
AU  - Stanojević, Aleksandar
AU  - Kulić, Adrijana
AU  - Libek, Vesna
AU  - Resanović, Ivana
AU  - Isenović, Esma R.
PY  - 2017
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/10156
AB  - U okviru ovog rada prikazan je slučaj bolesnika sa komplikovanim akutnim dislipidemijskim pankreatitisom u čijem je zbrinjavanju učestvovao tim, koji su činili endokrinolozi, gastroenterolozi i transfuziolozi. Dislipidemija, prevashodno tip IV dislipidemije, predstavlja čest uzrok nastanka akutnog pankreatitisa u populaciji mladih ljudi, posebno u slučajevima nezadovoljavajuće komplijanse (neredovno uzimanje preporučenih fibrata i nepridržavanje higijensko-dijetetskog režima). Tretman akutnog pankreatitisa se nezavisno od etiologije, zbog težine stanja, kompleksnosti lečenja i monitoringa bolesnika, sprovodi u Jedinicama intenzivnog lečenja. U slučajevima kada je dislipidemija uzrok akutnog pankreatitisa, često se u sklopu akutnog zbrinjavanja sprovodi i terapijska izmena plazme, kojom se brzo i značajno koriguju nivoi lipida, prevashodno triglicerida. Terapijska izmena plazme zahteva aktivnost transfuzioloških ekipa, koje su u manjim centrima, često nedostupne.
AB  - This article presents a case of patient with acute and complicated dyslipidaemic pancreatitis, managed by team, consisted of the endocrinologists, gastroenterologists and transfusiologists. Dyslipidaemia, predominantly type IV, is a common cause of acute pancreatitis in young patients, especially in the cases of poor compliance (irregular taking of recommended fibrates and failure to comply with the dietary regime). The treatment of acute pancreatitis, regardless of the aetiology, is due to the severity of the condition, the complexity of the treatment, and the monitoring of patients, in the Intensive Care Units. In cases where dyslipidaemia is the cause of acute pancreatitis, in the context of acute care, a therapeutic plasma exchange is often performed. It rapidly and significantly corrects lipid levels, primarily triglycerides. Therapeutic plasma exchange requires the activity of transfusiology team, which are often unavailable in smaller hospitals.
T2  - Materia medica
T1  - Prikaz timskog zbrinjavanja obolelog od akutnog teškog dislipidemijskog pankreatitisa - iskustvo jednog tercijernog zdravstvenog centra
T1  - The team management of patient suffered of acute severe dyslipidaemic pancreatitis: The experience of one tertiary health centre
VL  - 33
IS  - 3
SP  - 1557
EP  - 1562
DO  - 10.5937/MatMed1703557P
ER  - 

@article{
author = "Popin-Tarić, Marija and Gluvić, Zoran and Mitrović, Bojan and Samardžić, Vladimir and Lačković, Milena and Vasić-Vlaisavljević, Anita and Stanojević, Aleksandar and Kulić, Adrijana and Libek, Vesna and Resanović, Ivana and Isenović, Esma R.",
year = "2017",
abstract = "U okviru ovog rada prikazan je slučaj bolesnika sa komplikovanim akutnim dislipidemijskim pankreatitisom u čijem je zbrinjavanju učestvovao tim, koji su činili endokrinolozi, gastroenterolozi i transfuziolozi. Dislipidemija, prevashodno tip IV dislipidemije, predstavlja čest uzrok nastanka akutnog pankreatitisa u populaciji mladih ljudi, posebno u slučajevima nezadovoljavajuće komplijanse (neredovno uzimanje preporučenih fibrata i nepridržavanje higijensko-dijetetskog režima). Tretman akutnog pankreatitisa se nezavisno od etiologije, zbog težine stanja, kompleksnosti lečenja i monitoringa bolesnika, sprovodi u Jedinicama intenzivnog lečenja. U slučajevima kada je dislipidemija uzrok akutnog pankreatitisa, često se u sklopu akutnog zbrinjavanja sprovodi i terapijska izmena plazme, kojom se brzo i značajno koriguju nivoi lipida, prevashodno triglicerida. Terapijska izmena plazme zahteva aktivnost transfuzioloških ekipa, koje su u manjim centrima, često nedostupne., This article presents a case of patient with acute and complicated dyslipidaemic pancreatitis, managed by team, consisted of the endocrinologists, gastroenterologists and transfusiologists. Dyslipidaemia, predominantly type IV, is a common cause of acute pancreatitis in young patients, especially in the cases of poor compliance (irregular taking of recommended fibrates and failure to comply with the dietary regime). The treatment of acute pancreatitis, regardless of the aetiology, is due to the severity of the condition, the complexity of the treatment, and the monitoring of patients, in the Intensive Care Units. In cases where dyslipidaemia is the cause of acute pancreatitis, in the context of acute care, a therapeutic plasma exchange is often performed. It rapidly and significantly corrects lipid levels, primarily triglycerides. Therapeutic plasma exchange requires the activity of transfusiology team, which are often unavailable in smaller hospitals.",
journal = "Materia medica",
title = "Prikaz timskog zbrinjavanja obolelog od akutnog teškog dislipidemijskog pankreatitisa - iskustvo jednog tercijernog zdravstvenog centra, The team management of patient suffered of acute severe dyslipidaemic pancreatitis: The experience of one tertiary health centre",
volume = "33",
number = "3",
pages = "1557-1562",
doi = "10.5937/MatMed1703557P"
}

Popin-Tarić, M., Gluvić, Z., Mitrović, B., Samardžić, V., Lačković, M., Vasić-Vlaisavljević, A., Stanojević, A., Kulić, A., Libek, V., Resanović, I.,& Isenović, E. R.. (2017). Prikaz timskog zbrinjavanja obolelog od akutnog teškog dislipidemijskog pankreatitisa - iskustvo jednog tercijernog zdravstvenog centra. in Materia medica, 33(3), 1557-1562.
https://doi.org/10.5937/MatMed1703557P

Popin-Tarić M, Gluvić Z, Mitrović B, Samardžić V, Lačković M, Vasić-Vlaisavljević A, Stanojević A, Kulić A, Libek V, Resanović I, Isenović ER. Prikaz timskog zbrinjavanja obolelog od akutnog teškog dislipidemijskog pankreatitisa - iskustvo jednog tercijernog zdravstvenog centra. in Materia medica. 2017;33(3):1557-1562.
doi:10.5937/MatMed1703557P .

Popin-Tarić, Marija, Gluvić, Zoran, Mitrović, Bojan, Samardžić, Vladimir, Lačković, Milena, Vasić-Vlaisavljević, Anita, Stanojević, Aleksandar, Kulić, Adrijana, Libek, Vesna, Resanović, Ivana, Isenović, Esma R., "Prikaz timskog zbrinjavanja obolelog od akutnog teškog dislipidemijskog pankreatitisa - iskustvo jednog tercijernog zdravstvenog centra" in Materia medica, 33, no. 3 (2017):1557-1562,
https://doi.org/10.5937/MatMed1703557P . .

TY  - JOUR
AU  - Stanimirović, Julijana
AU  - Obradović, Milan M.
AU  - Zafirović, Sonja
AU  - Resanović, Ivana
AU  - Bogdanović, Nikola
AU  - Gluvić, Zoran
AU  - Mousa, Shaker A.
AU  - Isenović, Esma R.
PY  - 2015
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/511
AB  - An altered hepatic lipid metabolism involves multifactorial pathologies such as hepatic inflammation, insulin resistance and oxidative stress. Immunity has an essential role in the regulation of glucose and lipid metabolism in the liver. Inducible nitric oxide (NO) synthase (iNOS) has been proposed as an important factor that interplays between immunity and energy metabolism and also in the pathogenesis of obesity-linked insulin resistance. In the liver, locally produced NO plays a protective role during inflammation, and the balance of NO protective and cytotoxic effects is very important. This review is focused on understanding the molecular mechanisms of iNOS regulation in the state of altered hepatic lipid metabolism, which is critical for developing new strategies for treatment of hepatic disorders.
T2  - Clinical Lipidology
T1  - Effects of altered hepatic lipid metabolism on regulation of hepatic iNOS
VL  - 10
IS  - 2
SP  - 167
EP  - 175
DO  - 10.2217/CLP.15.8
ER  - 

@article{
author = "Stanimirović, Julijana and Obradović, Milan M. and Zafirović, Sonja and Resanović, Ivana and Bogdanović, Nikola and Gluvić, Zoran and Mousa, Shaker A. and Isenović, Esma R.",
year = "2015",
abstract = "An altered hepatic lipid metabolism involves multifactorial pathologies such as hepatic inflammation, insulin resistance and oxidative stress. Immunity has an essential role in the regulation of glucose and lipid metabolism in the liver. Inducible nitric oxide (NO) synthase (iNOS) has been proposed as an important factor that interplays between immunity and energy metabolism and also in the pathogenesis of obesity-linked insulin resistance. In the liver, locally produced NO plays a protective role during inflammation, and the balance of NO protective and cytotoxic effects is very important. This review is focused on understanding the molecular mechanisms of iNOS regulation in the state of altered hepatic lipid metabolism, which is critical for developing new strategies for treatment of hepatic disorders.",
journal = "Clinical Lipidology",
title = "Effects of altered hepatic lipid metabolism on regulation of hepatic iNOS",
volume = "10",
number = "2",
pages = "167-175",
doi = "10.2217/CLP.15.8"
}

Stanimirović, J., Obradović, M. M., Zafirović, S., Resanović, I., Bogdanović, N., Gluvić, Z., Mousa, S. A.,& Isenović, E. R.. (2015). Effects of altered hepatic lipid metabolism on regulation of hepatic iNOS. in Clinical Lipidology, 10(2), 167-175.
https://doi.org/10.2217/CLP.15.8

Stanimirović J, Obradović MM, Zafirović S, Resanović I, Bogdanović N, Gluvić Z, Mousa SA, Isenović ER. Effects of altered hepatic lipid metabolism on regulation of hepatic iNOS. in Clinical Lipidology. 2015;10(2):167-175.
doi:10.2217/CLP.15.8 .

Stanimirović, Julijana, Obradović, Milan M., Zafirović, Sonja, Resanović, Ivana, Bogdanović, Nikola, Gluvić, Zoran, Mousa, Shaker A., Isenović, Esma R., "Effects of altered hepatic lipid metabolism on regulation of hepatic iNOS" in Clinical Lipidology, 10, no. 2 (2015):167-175,
https://doi.org/10.2217/CLP.15.8 . .

TY  - JOUR
AU  - Trpković, Andreja
AU  - Resanović, Ivana
AU  - Stanimirović, Julijana
AU  - Radak, Đorđe J.
AU  - Mousa, Shaker A.
AU  - Cenić-Milošević, Desanka
AU  - Jevremovic, Danimir
AU  - Isenović, Esma R.
PY  - 2015
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/635
AB  - Atherosclerosis is a life-long illness that begins with risk factors, which in turn contribute to the development of subclinical disease, followed by the establishment of overt cardiovascular disease (CVD). Thrombotic-occlusive complications of atherosclerosis are among the most widespread and costly health problems. Oxidized low-density lipoprotein (OxLDL) plays an important role in atherogenesis by promoting an inflammatory environment and lipid deposition in the arterial wall. As cardiovascular events occur in individuals without common risk factors, there is a need for additional tools that may help in CVD risk assessment and management. The use of biomarkers has improved diagnostic, therapeutic and prognostic outcome in cardiovascular medicine. This review elaborates on the value of circulating OxLDL as a biomarker of CVD. Three enzyme-linked immunosorbent assays (4E6, DLH3 and E06) using murine monoclonal antibodies for determination of OxLDL blood levels have been developed. However, none of these assays are currently approved for routine clinical practice. We identified studies investigating OxLDL in CVD (measured by 4E6, DLH3 or E06 assay) by searching the PubMed database. Circulating OxLDL was found to be associated with all stages of atherosclerosis, from early atherogenesis to hypertension, coronary and peripheral arterial disease, acute coronary syndromes and ischemic cerebral infarction. The results of studies investigating the usefulness of OxLDL for CVD prediction were also summarized. Furthermore, OxLDL was found to be associated with pathologic conditions linked to CVD, including diabetes mellitus, obesity and metabolic syndrome (MetS). In addition, we have addressed the mechanisms by which OxLDL promotes atherogenesis, and the effects of antiatherogenic treatments on circulating OxLDL. Finally, we highlight the evidence suggesting that lipoprotein (a) [ Lp(a)] is the preferential carrier of oxidized phospholipids (OxPL) in human plasma. A strong association between OxPLapoB level (representing the content of OxPL on apolipoprotein B-100 particles, measured by E06 assay) and Lp(a) has been determined.
T2  - Critical Reviews in Clinical Laboratory Sciences
T1  - Oxidized low-density lipoprotein as a biomarker of cardiovascular diseases
VL  - 52
IS  - 2
SP  - 70
EP  - 85
DO  - 10.3109/10408363.2014.992063
ER  - 

@article{
author = "Trpković, Andreja and Resanović, Ivana and Stanimirović, Julijana and Radak, Đorđe J. and Mousa, Shaker A. and Cenić-Milošević, Desanka and Jevremovic, Danimir and Isenović, Esma R.",
year = "2015",
abstract = "Atherosclerosis is a life-long illness that begins with risk factors, which in turn contribute to the development of subclinical disease, followed by the establishment of overt cardiovascular disease (CVD). Thrombotic-occlusive complications of atherosclerosis are among the most widespread and costly health problems. Oxidized low-density lipoprotein (OxLDL) plays an important role in atherogenesis by promoting an inflammatory environment and lipid deposition in the arterial wall. As cardiovascular events occur in individuals without common risk factors, there is a need for additional tools that may help in CVD risk assessment and management. The use of biomarkers has improved diagnostic, therapeutic and prognostic outcome in cardiovascular medicine. This review elaborates on the value of circulating OxLDL as a biomarker of CVD. Three enzyme-linked immunosorbent assays (4E6, DLH3 and E06) using murine monoclonal antibodies for determination of OxLDL blood levels have been developed. However, none of these assays are currently approved for routine clinical practice. We identified studies investigating OxLDL in CVD (measured by 4E6, DLH3 or E06 assay) by searching the PubMed database. Circulating OxLDL was found to be associated with all stages of atherosclerosis, from early atherogenesis to hypertension, coronary and peripheral arterial disease, acute coronary syndromes and ischemic cerebral infarction. The results of studies investigating the usefulness of OxLDL for CVD prediction were also summarized. Furthermore, OxLDL was found to be associated with pathologic conditions linked to CVD, including diabetes mellitus, obesity and metabolic syndrome (MetS). In addition, we have addressed the mechanisms by which OxLDL promotes atherogenesis, and the effects of antiatherogenic treatments on circulating OxLDL. Finally, we highlight the evidence suggesting that lipoprotein (a) [ Lp(a)] is the preferential carrier of oxidized phospholipids (OxPL) in human plasma. A strong association between OxPLapoB level (representing the content of OxPL on apolipoprotein B-100 particles, measured by E06 assay) and Lp(a) has been determined.",
journal = "Critical Reviews in Clinical Laboratory Sciences",
title = "Oxidized low-density lipoprotein as a biomarker of cardiovascular diseases",
volume = "52",
number = "2",
pages = "70-85",
doi = "10.3109/10408363.2014.992063"
}

Trpković, A., Resanović, I., Stanimirović, J., Radak, Đ. J., Mousa, S. A., Cenić-Milošević, D., Jevremovic, D.,& Isenović, E. R.. (2015). Oxidized low-density lipoprotein as a biomarker of cardiovascular diseases. in Critical Reviews in Clinical Laboratory Sciences, 52(2), 70-85.
https://doi.org/10.3109/10408363.2014.992063

Trpković A, Resanović I, Stanimirović J, Radak ĐJ, Mousa SA, Cenić-Milošević D, Jevremovic D, Isenović ER. Oxidized low-density lipoprotein as a biomarker of cardiovascular diseases. in Critical Reviews in Clinical Laboratory Sciences. 2015;52(2):70-85.
doi:10.3109/10408363.2014.992063 .

Trpković, Andreja, Resanović, Ivana, Stanimirović, Julijana, Radak, Đorđe J., Mousa, Shaker A., Cenić-Milošević, Desanka, Jevremovic, Danimir, Isenović, Esma R., "Oxidized low-density lipoprotein as a biomarker of cardiovascular diseases" in Critical Reviews in Clinical Laboratory Sciences, 52, no. 2 (2015):70-85,
https://doi.org/10.3109/10408363.2014.992063 . .

TY  - JOUR
AU  - Resanović, Ivana
AU  - Sudar-Milovanović, Emina
AU  - Bogdanović, Nikola
AU  - Jovanović, Aleksandra
AU  - Zafirović, Sonja
AU  - Panić, Anastasija
AU  - Isenović, Esma R.
PY  - 2015
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/10316
AB  - Apoptoza je evolutivno očuvan mehanizam programirane ćelijske smrti, koji ima važnu ulogu u fiziološkim procesima, kao što su embrionalno razviće, hromonima regulisana ćelijska smrt, funkcionisanje imunog sistema i uklanjanje oštećenih ćelija. Dva osnovna puta indukcije apoptoze su unutrašnji i spoljašnji. Dok unutrašnji put apoptoze može pokrenuti unutarćeljska akumulacija Ca 2+ jona, koja je praćena permeabilizacijom membrane mitohondrija i oslobađanjem pro-apoptotskih proteina iz mitohondrija u citoplazmu, spoljašnji put uključuje aktivaciju membransih receptora za TNF-a (engl. Tumor Necrosis Factor-a), kao što su TNFR-1 (engl. Tumor Necrosis Factor receptor 1), Fas, i TRAIL-R (engl. TNF-related apoptosis-inducing ligand receptors). Pored toga, postoji i perforin-granzim put koji uključuje aktivaciju citotoksičnih T-limfocita. Sva tri puta rezultiraju fragmentacijom DNK, degradacijom citoskeleta i nuklearnih proteina, unakrsnim povezivanjem proteina, formiranjem apoptotskih tela, ekspresijom liganada za receptore na fagocitima i na kraju fagocitozom. U ovoj reviji su objedinjeni podaci iz nedavno objavljenih studija koje su fokusirane na proteine uključene u proces apoptoze i molekularne mehanizme apoptoze. Razumevanje mehanizama apoptoze može da pruži korisne informacije i nove pristupe u prevenciji i razvoju novih terapija za različite bolesti.
AB  - Apoptosis is evolutionary conserved, programmed pattern of cell death with an essential role in various physiological processes, such as normal cell turnover and embryonic development, hormone-regulated cell demise, aging, immune system functioning and development and removal of defective and harmful cells. There are two general pathways for activation of apoptosis: the intrinsic and extrinsic pathways. While the intrinsic apoptotic pathway can be triggered by a cytotoxic accumulation of intracellular Ca 2+ , followed permeabilization of mitochondrial membrane and release of pro-apoptotic proteins into the cytosol from mitochondria, the extrinsic mechanisms of apoptosis include the participation of death receptors of tumor necrosis factor-a (TNF-a), receptor superfamily such as TNFR-1, Fas, and TNF-related apoptosis-inducing ligand receptors (TRAIL-R) located on the plasma membrane. There is also the perforin-granzyme pathway that involves T-cell mediated cytotoxicity. All three pathways converge on the same execution pathway, resulting in DNA fragmentation, degradation of cytoskeletal and nuclear proteins, cross-linking of proteins, formation of apoptotic bodies, expression of ligands for phagocytic cell receptors and finally uptake by phagocytic cells. In this review we summarize data from recent studies focusing on apoptotic proteins that have been identified and molecular mechanisms of apoptosis. Understanding apoptotic mechanism might provide useful information and a new approach to prevention and development of new therapies for variety of diseases.
T2  - Medicinska istraživanja
T1  - Osnove apoptoze
T1  - Fundamentals of apoptosis
VL  - 49
IS  - 2
SP  - 42
EP  - 45
DO  - 10.5937/MedIst1502042R
ER  - 

@article{
author = "Resanović, Ivana and Sudar-Milovanović, Emina and Bogdanović, Nikola and Jovanović, Aleksandra and Zafirović, Sonja and Panić, Anastasija and Isenović, Esma R.",
year = "2015",
abstract = "Apoptoza je evolutivno očuvan mehanizam programirane ćelijske smrti, koji ima važnu ulogu u fiziološkim procesima, kao što su embrionalno razviće, hromonima regulisana ćelijska smrt, funkcionisanje imunog sistema i uklanjanje oštećenih ćelija. Dva osnovna puta indukcije apoptoze su unutrašnji i spoljašnji. Dok unutrašnji put apoptoze može pokrenuti unutarćeljska akumulacija Ca 2+ jona, koja je praćena permeabilizacijom membrane mitohondrija i oslobađanjem pro-apoptotskih proteina iz mitohondrija u citoplazmu, spoljašnji put uključuje aktivaciju membransih receptora za TNF-a (engl. Tumor Necrosis Factor-a), kao što su TNFR-1 (engl. Tumor Necrosis Factor receptor 1), Fas, i TRAIL-R (engl. TNF-related apoptosis-inducing ligand receptors). Pored toga, postoji i perforin-granzim put koji uključuje aktivaciju citotoksičnih T-limfocita. Sva tri puta rezultiraju fragmentacijom DNK, degradacijom citoskeleta i nuklearnih proteina, unakrsnim povezivanjem proteina, formiranjem apoptotskih tela, ekspresijom liganada za receptore na fagocitima i na kraju fagocitozom. U ovoj reviji su objedinjeni podaci iz nedavno objavljenih studija koje su fokusirane na proteine uključene u proces apoptoze i molekularne mehanizme apoptoze. Razumevanje mehanizama apoptoze može da pruži korisne informacije i nove pristupe u prevenciji i razvoju novih terapija za različite bolesti., Apoptosis is evolutionary conserved, programmed pattern of cell death with an essential role in various physiological processes, such as normal cell turnover and embryonic development, hormone-regulated cell demise, aging, immune system functioning and development and removal of defective and harmful cells. There are two general pathways for activation of apoptosis: the intrinsic and extrinsic pathways. While the intrinsic apoptotic pathway can be triggered by a cytotoxic accumulation of intracellular Ca 2+ , followed permeabilization of mitochondrial membrane and release of pro-apoptotic proteins into the cytosol from mitochondria, the extrinsic mechanisms of apoptosis include the participation of death receptors of tumor necrosis factor-a (TNF-a), receptor superfamily such as TNFR-1, Fas, and TNF-related apoptosis-inducing ligand receptors (TRAIL-R) located on the plasma membrane. There is also the perforin-granzyme pathway that involves T-cell mediated cytotoxicity. All three pathways converge on the same execution pathway, resulting in DNA fragmentation, degradation of cytoskeletal and nuclear proteins, cross-linking of proteins, formation of apoptotic bodies, expression of ligands for phagocytic cell receptors and finally uptake by phagocytic cells. In this review we summarize data from recent studies focusing on apoptotic proteins that have been identified and molecular mechanisms of apoptosis. Understanding apoptotic mechanism might provide useful information and a new approach to prevention and development of new therapies for variety of diseases.",
journal = "Medicinska istraživanja",
title = "Osnove apoptoze, Fundamentals of apoptosis",
volume = "49",
number = "2",
pages = "42-45",
doi = "10.5937/MedIst1502042R"
}

Resanović, I., Sudar-Milovanović, E., Bogdanović, N., Jovanović, A., Zafirović, S., Panić, A.,& Isenović, E. R.. (2015). Osnove apoptoze. in Medicinska istraživanja, 49(2), 42-45.
https://doi.org/10.5937/MedIst1502042R

Resanović I, Sudar-Milovanović E, Bogdanović N, Jovanović A, Zafirović S, Panić A, Isenović ER. Osnove apoptoze. in Medicinska istraživanja. 2015;49(2):42-45.
doi:10.5937/MedIst1502042R .

Resanović, Ivana, Sudar-Milovanović, Emina, Bogdanović, Nikola, Jovanović, Aleksandra, Zafirović, Sonja, Panić, Anastasija, Isenović, Esma R., "Osnove apoptoze" in Medicinska istraživanja, 49, no. 2 (2015):42-45,
https://doi.org/10.5937/MedIst1502042R . .

TY  - JOUR
AU  - Trpković, Andreja
AU  - Stanimirović, Julijana
AU  - Rizzo, Manfredi
AU  - Resanović, Ivana
AU  - Soskić, Sanja S.
AU  - Jevremovic, Danimir
AU  - Isenović, Esma R.
PY  - 2015
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/613
AB  - The assessment of cardiovascular risk and treatment of cardiovascular diseases are major public health issues worldwide. Inflammation is now recognized as a key regulatory process that links multiple risk factors for atherosclerosis. The substantial number of patients having cardiovascular events lack commonly established risk factors. The utility of high-sensitivity C-reactive protein (hsCRP), a circulating biomarker related to inflammation, may provide additional information in risk prediction. This review will consider the impact of hsCRP level on initiation of statin therapy.
T2  - Angiology
T1  - High-Sensitivity C-Reactive Protein and Statin Initiation
VL  - 66
IS  - 6
SP  - 503
EP  - 507
DO  - 10.1177/0003319714543000
ER  - 

@article{
author = "Trpković, Andreja and Stanimirović, Julijana and Rizzo, Manfredi and Resanović, Ivana and Soskić, Sanja S. and Jevremovic, Danimir and Isenović, Esma R.",
year = "2015",
abstract = "The assessment of cardiovascular risk and treatment of cardiovascular diseases are major public health issues worldwide. Inflammation is now recognized as a key regulatory process that links multiple risk factors for atherosclerosis. The substantial number of patients having cardiovascular events lack commonly established risk factors. The utility of high-sensitivity C-reactive protein (hsCRP), a circulating biomarker related to inflammation, may provide additional information in risk prediction. This review will consider the impact of hsCRP level on initiation of statin therapy.",
journal = "Angiology",
title = "High-Sensitivity C-Reactive Protein and Statin Initiation",
volume = "66",
number = "6",
pages = "503-507",
doi = "10.1177/0003319714543000"
}

Trpković, A., Stanimirović, J., Rizzo, M., Resanović, I., Soskić, S. S., Jevremovic, D.,& Isenović, E. R.. (2015). High-Sensitivity C-Reactive Protein and Statin Initiation. in Angiology, 66(6), 503-507.
https://doi.org/10.1177/0003319714543000

Trpković A, Stanimirović J, Rizzo M, Resanović I, Soskić SS, Jevremovic D, Isenović ER. High-Sensitivity C-Reactive Protein and Statin Initiation. in Angiology. 2015;66(6):503-507.
doi:10.1177/0003319714543000 .

Trpković, Andreja, Stanimirović, Julijana, Rizzo, Manfredi, Resanović, Ivana, Soskić, Sanja S., Jevremovic, Danimir, Isenović, Esma R., "High-Sensitivity C-Reactive Protein and Statin Initiation" in Angiology, 66, no. 6 (2015):503-507,
https://doi.org/10.1177/0003319714543000 . .

TY  - JOUR
AU  - Trpković, Andreja
AU  - Stanimirović, Julijana
AU  - Resanović, Ivana
AU  - Otasevic, Petar
AU  - Jevremovic, Danimir
AU  - Radak, Đorđe J.
AU  - Isenović, Esma R.
PY  - 2015
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/312
AB  - It is now recognized that inflammatory processes regulate all stages of atherosclerosis, from disease initiation to thrombotic complications. C-reactive protein (CRP) is a plasmatic protein used as a general marker of inflammation. The high sensitivity C-reactive protein (hsCRP) refers to the measurement of CRP in blood samples using assays with sufficient sensitivity to quantify low (baseline) levels of this biomarker. Low-grade chronic inflammatory processes are linked to atherosclerosis and may be screened with the use of hsCRP, thus providing additional information in cardiovascular risk prediction. This review elaborates the role of CRP in atherogenesis and the value of hsCRP as a biomarker in cardiovascular risk prediction in both primary and secondary prevention setting.
T2  - Current Pharmaceutical Analysis
T1  - High Sensitivity C-reactive Protein and Cardiovascular Risk Prediction
VL  - 11
IS  - 1
SP  - 60
EP  - 65
DO  - 10.2174/1573412910666140822003911
ER  - 

@article{
author = "Trpković, Andreja and Stanimirović, Julijana and Resanović, Ivana and Otasevic, Petar and Jevremovic, Danimir and Radak, Đorđe J. and Isenović, Esma R.",
year = "2015",
abstract = "It is now recognized that inflammatory processes regulate all stages of atherosclerosis, from disease initiation to thrombotic complications. C-reactive protein (CRP) is a plasmatic protein used as a general marker of inflammation. The high sensitivity C-reactive protein (hsCRP) refers to the measurement of CRP in blood samples using assays with sufficient sensitivity to quantify low (baseline) levels of this biomarker. Low-grade chronic inflammatory processes are linked to atherosclerosis and may be screened with the use of hsCRP, thus providing additional information in cardiovascular risk prediction. This review elaborates the role of CRP in atherogenesis and the value of hsCRP as a biomarker in cardiovascular risk prediction in both primary and secondary prevention setting.",
journal = "Current Pharmaceutical Analysis",
title = "High Sensitivity C-reactive Protein and Cardiovascular Risk Prediction",
volume = "11",
number = "1",
pages = "60-65",
doi = "10.2174/1573412910666140822003911"
}

Trpković, A., Stanimirović, J., Resanović, I., Otasevic, P., Jevremovic, D., Radak, Đ. J.,& Isenović, E. R.. (2015). High Sensitivity C-reactive Protein and Cardiovascular Risk Prediction. in Current Pharmaceutical Analysis, 11(1), 60-65.
https://doi.org/10.2174/1573412910666140822003911

Trpković A, Stanimirović J, Resanović I, Otasevic P, Jevremovic D, Radak ĐJ, Isenović ER. High Sensitivity C-reactive Protein and Cardiovascular Risk Prediction. in Current Pharmaceutical Analysis. 2015;11(1):60-65.
doi:10.2174/1573412910666140822003911 .

Trpković, Andreja, Stanimirović, Julijana, Resanović, Ivana, Otasevic, Petar, Jevremovic, Danimir, Radak, Đorđe J., Isenović, Esma R., "High Sensitivity C-reactive Protein and Cardiovascular Risk Prediction" in Current Pharmaceutical Analysis, 11, no. 1 (2015):60-65,
https://doi.org/10.2174/1573412910666140822003911 . .

TY  - JOUR
AU  - Radak, Đorđe J.
AU  - Resanović, Ivana
AU  - Isenović, Esma R.
PY  - 2014
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/79
AB  - The pathogenesis of acute brain ischemia (ABI) is highly complex and involves multiple mechanisms including free radical generation. Imbalance between the cellular production of free radicals and the ability of cells to defend against them is referred to as oxidative stress. Oxidative stress is one of the mechanisms contributing to neuronal damage, potentially induced through the ABI. Through interactions with a large number of molecules, reactive oxygen species may irreversibly destroy or alter the function of the cellular lipids, proteins, and nucleic acids and initiate cell signaling pathways after cerebral ischemia. Future investigations should focus on the understanding of oxidative stress mechanisms and neuro-protection in order to discover new treatment targets.
T2  - Angiology
T1  - Link Between Oxidative Stress and Acute Brain Ischemia
VL  - 65
IS  - 8
SP  - 667
EP  - 676
DO  - 10.1177/0003319713506516
ER  - 

@article{
author = "Radak, Đorđe J. and Resanović, Ivana and Isenović, Esma R.",
year = "2014",
abstract = "The pathogenesis of acute brain ischemia (ABI) is highly complex and involves multiple mechanisms including free radical generation. Imbalance between the cellular production of free radicals and the ability of cells to defend against them is referred to as oxidative stress. Oxidative stress is one of the mechanisms contributing to neuronal damage, potentially induced through the ABI. Through interactions with a large number of molecules, reactive oxygen species may irreversibly destroy or alter the function of the cellular lipids, proteins, and nucleic acids and initiate cell signaling pathways after cerebral ischemia. Future investigations should focus on the understanding of oxidative stress mechanisms and neuro-protection in order to discover new treatment targets.",
journal = "Angiology",
title = "Link Between Oxidative Stress and Acute Brain Ischemia",
volume = "65",
number = "8",
pages = "667-676",
doi = "10.1177/0003319713506516"
}

Radak, Đ. J., Resanović, I.,& Isenović, E. R.. (2014). Link Between Oxidative Stress and Acute Brain Ischemia. in Angiology, 65(8), 667-676.
https://doi.org/10.1177/0003319713506516

Radak ĐJ, Resanović I, Isenović ER. Link Between Oxidative Stress and Acute Brain Ischemia. in Angiology. 2014;65(8):667-676.
doi:10.1177/0003319713506516 .

Radak, Đorđe J., Resanović, Ivana, Isenović, Esma R., "Link Between Oxidative Stress and Acute Brain Ischemia" in Angiology, 65, no. 8 (2014):667-676,
https://doi.org/10.1177/0003319713506516 . .

TY  - JOUR
AU  - Kypreos, Kyriakos E.
AU  - Zafirović, Sonja
AU  - Petropoulou, Peristera-Ioanna
AU  - Bjelogrlic, Predrag
AU  - Resanović, Ivana
AU  - Traish, Abdul
AU  - Isenović, Esma R.
PY  - 2014
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/5954
AB  - Estrogens have been recognized, in the last 3 decades, as important hormones in direct and indirect modulation of vascular health. In addition to their direct benefit on cardiovascular health, the presence of esterified estrogen in the lipid core of high-density lipoprotein (HDL) particles indirectly contributes to atheroprotection by significantly improving HDL quality and functionality. Estrogens modulate their physiological activity via genomic and nongenomic mechanisms. Genomic mechanisms are thought to be mediated directly by interaction of the hormone receptor complex with the hormone response elements that regulate gene expression. Nongenomic mechanisms are thought to occur via interaction of the estrogen with membrane-bound receptors, which rapidly activate intracellular signaling without binding of the hormone receptor complex to its hormone response elements. Estradiol in particular mediates early and late endothelial nitric oxide synthase (eNOS) activation via interaction with estrogen receptors through both nongenomic and genomic mechanisms. In the vascular system, the primary endogenous source of nitric oxide (NO) generation is eNOS. Nitric oxide primarily influences blood vessel relaxation, the heart rate, and myocyte contractility. The abnormalities in expression and/or functions of eNOS lead to the development of cardiovascular diseases, both in animals and in humans. Although considerable research efforts have been dedicated to understanding the mechanisms of action of estradiol in regulating cardiac eNOS, more research is needed to fully understand the details of such mechanisms. This review focuses on recent findings from animal and human studies on the regulation of eNOS and HDL quality by estradiol in cardiovascular pathology.
T2  - Journal of Cardiovascular Pharmacology and Therapeutics
T1  - Regulation of Endothelial Nitric Oxide Synthase and High-Density Lipoprotein Quality by Estradiol in Cardiovascular Pathology
VL  - 19
IS  - 3
SP  - 256
EP  - 268
DO  - 10.1177/1074248413513499
ER  - 

@article{
author = "Kypreos, Kyriakos E. and Zafirović, Sonja and Petropoulou, Peristera-Ioanna and Bjelogrlic, Predrag and Resanović, Ivana and Traish, Abdul and Isenović, Esma R.",
year = "2014",
abstract = "Estrogens have been recognized, in the last 3 decades, as important hormones in direct and indirect modulation of vascular health. In addition to their direct benefit on cardiovascular health, the presence of esterified estrogen in the lipid core of high-density lipoprotein (HDL) particles indirectly contributes to atheroprotection by significantly improving HDL quality and functionality. Estrogens modulate their physiological activity via genomic and nongenomic mechanisms. Genomic mechanisms are thought to be mediated directly by interaction of the hormone receptor complex with the hormone response elements that regulate gene expression. Nongenomic mechanisms are thought to occur via interaction of the estrogen with membrane-bound receptors, which rapidly activate intracellular signaling without binding of the hormone receptor complex to its hormone response elements. Estradiol in particular mediates early and late endothelial nitric oxide synthase (eNOS) activation via interaction with estrogen receptors through both nongenomic and genomic mechanisms. In the vascular system, the primary endogenous source of nitric oxide (NO) generation is eNOS. Nitric oxide primarily influences blood vessel relaxation, the heart rate, and myocyte contractility. The abnormalities in expression and/or functions of eNOS lead to the development of cardiovascular diseases, both in animals and in humans. Although considerable research efforts have been dedicated to understanding the mechanisms of action of estradiol in regulating cardiac eNOS, more research is needed to fully understand the details of such mechanisms. This review focuses on recent findings from animal and human studies on the regulation of eNOS and HDL quality by estradiol in cardiovascular pathology.",
journal = "Journal of Cardiovascular Pharmacology and Therapeutics",
title = "Regulation of Endothelial Nitric Oxide Synthase and High-Density Lipoprotein Quality by Estradiol in Cardiovascular Pathology",
volume = "19",
number = "3",
pages = "256-268",
doi = "10.1177/1074248413513499"
}

Kypreos, K. E., Zafirović, S., Petropoulou, P., Bjelogrlic, P., Resanović, I., Traish, A.,& Isenović, E. R.. (2014). Regulation of Endothelial Nitric Oxide Synthase and High-Density Lipoprotein Quality by Estradiol in Cardiovascular Pathology. in Journal of Cardiovascular Pharmacology and Therapeutics, 19(3), 256-268.
https://doi.org/10.1177/1074248413513499

Kypreos KE, Zafirović S, Petropoulou P, Bjelogrlic P, Resanović I, Traish A, Isenović ER. Regulation of Endothelial Nitric Oxide Synthase and High-Density Lipoprotein Quality by Estradiol in Cardiovascular Pathology. in Journal of Cardiovascular Pharmacology and Therapeutics. 2014;19(3):256-268.
doi:10.1177/1074248413513499 .

Kypreos, Kyriakos E., Zafirović, Sonja, Petropoulou, Peristera-Ioanna, Bjelogrlic, Predrag, Resanović, Ivana, Traish, Abdul, Isenović, Esma R., "Regulation of Endothelial Nitric Oxide Synthase and High-Density Lipoprotein Quality by Estradiol in Cardiovascular Pathology" in Journal of Cardiovascular Pharmacology and Therapeutics, 19, no. 3 (2014):256-268,
https://doi.org/10.1177/1074248413513499 . .

TY  - JOUR
AU  - Radak, Đorđe J.
AU  - Resanović, Ivana
AU  - Isenović, Esma R.
PY  - 2014
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/54
AB  - Acute brain ischemia caused by transient ischemic attack initiates a complex sequence of events in the central nervous system and hypothalamic-pituitary-adrenal (HPA) axis which may ultimately culminate in neuronal and cell damage. The brain is highly susceptible to ischemia and in response to stress shows changes in morphology and chemistry that are largely reversible. These responses are known to modify the function of the HPA axis, but their mechanisms are not yet clear. Duration and size of the HPA axis activation are regulated by corticotropin-releasing hormone, vasopressin (AVP), and glucocorticoids, including cortisol. Numerous studies suggest that activation of these hormones following brain ischemia can result in neurohormonal dysfunction that can exacerbate long-term prognosis following stroke. These studies represent evidence that changes in the HPA axis play an important role in brain ischemia.
T2  - Angiology
T1  - Changes in Hypothalamus-Pituitary-Adrenal Axis Following Transient Ischemic Attack
VL  - 65
IS  - 8
SP  - 723
EP  - 732
DO  - 10.1177/0003319713503487
ER  - 

@article{
author = "Radak, Đorđe J. and Resanović, Ivana and Isenović, Esma R.",
year = "2014",
abstract = "Acute brain ischemia caused by transient ischemic attack initiates a complex sequence of events in the central nervous system and hypothalamic-pituitary-adrenal (HPA) axis which may ultimately culminate in neuronal and cell damage. The brain is highly susceptible to ischemia and in response to stress shows changes in morphology and chemistry that are largely reversible. These responses are known to modify the function of the HPA axis, but their mechanisms are not yet clear. Duration and size of the HPA axis activation are regulated by corticotropin-releasing hormone, vasopressin (AVP), and glucocorticoids, including cortisol. Numerous studies suggest that activation of these hormones following brain ischemia can result in neurohormonal dysfunction that can exacerbate long-term prognosis following stroke. These studies represent evidence that changes in the HPA axis play an important role in brain ischemia.",
journal = "Angiology",
title = "Changes in Hypothalamus-Pituitary-Adrenal Axis Following Transient Ischemic Attack",
volume = "65",
number = "8",
pages = "723-732",
doi = "10.1177/0003319713503487"
}

Radak, Đ. J., Resanović, I.,& Isenović, E. R.. (2014). Changes in Hypothalamus-Pituitary-Adrenal Axis Following Transient Ischemic Attack. in Angiology, 65(8), 723-732.
https://doi.org/10.1177/0003319713503487

Radak ĐJ, Resanović I, Isenović ER. Changes in Hypothalamus-Pituitary-Adrenal Axis Following Transient Ischemic Attack. in Angiology. 2014;65(8):723-732.
doi:10.1177/0003319713503487 .

Radak, Đorđe J., Resanović, Ivana, Isenović, Esma R., "Changes in Hypothalamus-Pituitary-Adrenal Axis Following Transient Ischemic Attack" in Angiology, 65, no. 8 (2014):723-732,
https://doi.org/10.1177/0003319713503487 . .

TY  - JOUR
AU  - Savić, Kristina
AU  - Zafirović, Sonja
AU  - Resanović, Ivana
AU  - Sudar, Emina
AU  - Maravić-Stojković, Vera
AU  - Putniković, Biljana
AU  - Isenović, Esma R.
PY  - 2013
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/10320
AB  - Biomarkeri predstavljaju indikatore normalnih bioloških procesa, patogenih procesa ili farmakoloških odgovora na terapijske intervencije. Interleukin-6 (IL6, engl. Interleukin-6) je biomarker, čija sinteza može biti aktivirana različitim stimulusima, kao što su: interferon-g (IFN-g, engl. Interferon-g), faktor tumorske nekroze (TNF, engl. Tumor Necrosis Factor) i/ili interleukin-1 (IL-1, engl. Interleukin-1). IL-6 svoje efekte ostvaruje preko IL-6 receptora (IL-6R, engl. IL-6 Receptor). Pokazano je da kod transgenih miševa, kod kojih je indukovana ekspresija IL-6 i IL-6R, dolazi do hipertrofije miokarda. U mehanizmu hipertrofije miokarda bitnu ulogu ima i novootkriveni kardiotrofin1 (CT-1, engl. Cardiotrophin-1) koji je jedan od članova IL-6 familije. Aktivnost IL-6 vezuje se za razvoj aneurizme abdominalne aorte (AAA, engl. Abdominal Aortic Aneurysm), zapravo, pokazano je da su aneurizme mesta odakle cirkuliše IL-6, a takođe se smatra da je koncentracija IL-6 u pozitivnoj korelaciji sa dijametrim AAA. C-reaktivni protein (CRP, engl. CReactive Protein) je jedan od mnogobrojnih biomarkera kardiovaskularnih bolesti. Uloga CRP-a je u nastanku i progresiji kardiovaskularnih bolesti. Lokalna produkcija CRP-a od strane glatkih mišićnih i endotelnih ćelija krvnog suda, u velikoj meri utiče na razvoj procesa ateroskleroze. Važnu ulogu u nastanku ateroskleroze, osim CRP-a, ima i oksidovani lipoprotein male gustine (ox-LDL, engl. Oxidized Low Density Lipoprotein). Oksidaciju LDL-a vrše različiti enzimi. Ox-LDL nakon što prođe u intimu krvnog suda indukuje sakupljanje monocita, tj. monociti se prevode u makrofage koji vezuju ox-LDL. Kada se makrofagi napune ox-LDL-om, dolazi do pokretanja signala ćelijske smrti i stvaraju se forme penušavih ćelija koje čine početni deo aterosklerotičnog plaka. Nova saznanja o mehamizmu delovanja kao i uloge biomerkera u nastanku kardiovaskularnih bolesti, svakako će pružiti jednu od mogućnosti prevencije nastanka ovih poremećaja, a takođe i adekvatnu terapiju u lecenju kardiovaskularnih oboljenja, što i jeste jedan od glavnih ciljeva intezivnih istraživanja u oblasti biomarkera. U ovom preglednom članku, opisana su tri biomarkera kardiovaskularnih bolesti: IL-6, CRP i LDL.
AB  - Biomarkers are indicators of normal biological processes, pathogenic processes or pharmacologic responses to therapeutic interventions. Interleukin-6 (IL - 6) is a biomarker whose synthesis could be activated by various stimuli, such as interferon-g (IFN - g), tumor necrosis factor (TNF) and/or interleukin - 1 (IL - 1). IL - 6 achieves its effects through the IL-6 receptor (IL - 6R). It has been shown that transgenic mice, which have induced expression of IL - 6 and IL - 6R develop myocardial hypertrophy. In myocardial hypertrophy, an important role is played by a newly discovered cardiotrophin-1, a member of the IL - 6 family. The activity of IL - 6 is associated with the development of abdominal aortic aneurysm (AAA); in fact, it has been shown that the concentration of IL - 6 positively correlates with AAA diameters. C-reactive protein (CRP) is one of the biomarkers of cardiovascular diseases. Local production of CRP by the smooth muscular and endothelial cells of the vessel leads to the development of atherosclerosis to a large extent. Oxidized low-density lipoprotein (ox - LDL) also has an important role in the development of atherosclerosis. After penetrating the intima of the vessel, ox - LDL induces monocyte collection, i.e. monocytes are translated into macrophages that bind ox - LDL. Having filled the macrophages with ox - LDL, the signals of cell death are activated, which leads to the creation of foamy cells that make up the initial part of the atherosclerotic plaque. New knowledge about the mechanism of action and the role of biomarkers in the development of cardiovascular diseases will certainly provide an opportunity to prevent the onset of these disorders, as well as an adequate therapy in the treatment of cardiovascular diseases, which is one of the main goals of intensive research in the field of biomarkers.
T2  - Medicinska istraživanja
T1  - Biomarkeri u kardiovaskularnim bolestima
T1  - Biomarkers of cardiovascular diseases
VL  - 47
IS  - 2
SP  - 11
EP  - 19
DO  - 10.5937/MedIst1302011S
ER  - 

@article{
author = "Savić, Kristina and Zafirović, Sonja and Resanović, Ivana and Sudar, Emina and Maravić-Stojković, Vera and Putniković, Biljana and Isenović, Esma R.",
year = "2013",
abstract = "Biomarkeri predstavljaju indikatore normalnih bioloških procesa, patogenih procesa ili farmakoloških odgovora na terapijske intervencije. Interleukin-6 (IL6, engl. Interleukin-6) je biomarker, čija sinteza može biti aktivirana različitim stimulusima, kao što su: interferon-g (IFN-g, engl. Interferon-g), faktor tumorske nekroze (TNF, engl. Tumor Necrosis Factor) i/ili interleukin-1 (IL-1, engl. Interleukin-1). IL-6 svoje efekte ostvaruje preko IL-6 receptora (IL-6R, engl. IL-6 Receptor). Pokazano je da kod transgenih miševa, kod kojih je indukovana ekspresija IL-6 i IL-6R, dolazi do hipertrofije miokarda. U mehanizmu hipertrofije miokarda bitnu ulogu ima i novootkriveni kardiotrofin1 (CT-1, engl. Cardiotrophin-1) koji je jedan od članova IL-6 familije. Aktivnost IL-6 vezuje se za razvoj aneurizme abdominalne aorte (AAA, engl. Abdominal Aortic Aneurysm), zapravo, pokazano je da su aneurizme mesta odakle cirkuliše IL-6, a takođe se smatra da je koncentracija IL-6 u pozitivnoj korelaciji sa dijametrim AAA. C-reaktivni protein (CRP, engl. CReactive Protein) je jedan od mnogobrojnih biomarkera kardiovaskularnih bolesti. Uloga CRP-a je u nastanku i progresiji kardiovaskularnih bolesti. Lokalna produkcija CRP-a od strane glatkih mišićnih i endotelnih ćelija krvnog suda, u velikoj meri utiče na razvoj procesa ateroskleroze. Važnu ulogu u nastanku ateroskleroze, osim CRP-a, ima i oksidovani lipoprotein male gustine (ox-LDL, engl. Oxidized Low Density Lipoprotein). Oksidaciju LDL-a vrše različiti enzimi. Ox-LDL nakon što prođe u intimu krvnog suda indukuje sakupljanje monocita, tj. monociti se prevode u makrofage koji vezuju ox-LDL. Kada se makrofagi napune ox-LDL-om, dolazi do pokretanja signala ćelijske smrti i stvaraju se forme penušavih ćelija koje čine početni deo aterosklerotičnog plaka. Nova saznanja o mehamizmu delovanja kao i uloge biomerkera u nastanku kardiovaskularnih bolesti, svakako će pružiti jednu od mogućnosti prevencije nastanka ovih poremećaja, a takođe i adekvatnu terapiju u lecenju kardiovaskularnih oboljenja, što i jeste jedan od glavnih ciljeva intezivnih istraživanja u oblasti biomarkera. U ovom preglednom članku, opisana su tri biomarkera kardiovaskularnih bolesti: IL-6, CRP i LDL., Biomarkers are indicators of normal biological processes, pathogenic processes or pharmacologic responses to therapeutic interventions. Interleukin-6 (IL - 6) is a biomarker whose synthesis could be activated by various stimuli, such as interferon-g (IFN - g), tumor necrosis factor (TNF) and/or interleukin - 1 (IL - 1). IL - 6 achieves its effects through the IL-6 receptor (IL - 6R). It has been shown that transgenic mice, which have induced expression of IL - 6 and IL - 6R develop myocardial hypertrophy. In myocardial hypertrophy, an important role is played by a newly discovered cardiotrophin-1, a member of the IL - 6 family. The activity of IL - 6 is associated with the development of abdominal aortic aneurysm (AAA); in fact, it has been shown that the concentration of IL - 6 positively correlates with AAA diameters. C-reactive protein (CRP) is one of the biomarkers of cardiovascular diseases. Local production of CRP by the smooth muscular and endothelial cells of the vessel leads to the development of atherosclerosis to a large extent. Oxidized low-density lipoprotein (ox - LDL) also has an important role in the development of atherosclerosis. After penetrating the intima of the vessel, ox - LDL induces monocyte collection, i.e. monocytes are translated into macrophages that bind ox - LDL. Having filled the macrophages with ox - LDL, the signals of cell death are activated, which leads to the creation of foamy cells that make up the initial part of the atherosclerotic plaque. New knowledge about the mechanism of action and the role of biomarkers in the development of cardiovascular diseases will certainly provide an opportunity to prevent the onset of these disorders, as well as an adequate therapy in the treatment of cardiovascular diseases, which is one of the main goals of intensive research in the field of biomarkers.",
journal = "Medicinska istraživanja",
title = "Biomarkeri u kardiovaskularnim bolestima, Biomarkers of cardiovascular diseases",
volume = "47",
number = "2",
pages = "11-19",
doi = "10.5937/MedIst1302011S"
}

Savić, K., Zafirović, S., Resanović, I., Sudar, E., Maravić-Stojković, V., Putniković, B.,& Isenović, E. R.. (2013). Biomarkeri u kardiovaskularnim bolestima. in Medicinska istraživanja, 47(2), 11-19.
https://doi.org/10.5937/MedIst1302011S

Savić K, Zafirović S, Resanović I, Sudar E, Maravić-Stojković V, Putniković B, Isenović ER. Biomarkeri u kardiovaskularnim bolestima. in Medicinska istraživanja. 2013;47(2):11-19.
doi:10.5937/MedIst1302011S .

Savić, Kristina, Zafirović, Sonja, Resanović, Ivana, Sudar, Emina, Maravić-Stojković, Vera, Putniković, Biljana, Isenović, Esma R., "Biomarkeri u kardiovaskularnim bolestima" in Medicinska istraživanja, 47, no. 2 (2013):11-19,
https://doi.org/10.5937/MedIst1302011S . .

TY  - JOUR
AU  - Resanović, Ivana
AU  - Rizzo, Manfredi
AU  - Zafirović, Sonja
AU  - Bjelogrlic, P.
AU  - Perović, Milan
AU  - Savić, K.
AU  - Patti, A. M.
AU  - Isenović, Esma R.
PY  - 2013
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/5680
AB  - Estrogens are secreted primarily by the ovaries and placenta, by the testes in men and also produced by peripheral steroidogenic conversion. The 3 major naturally occurring estrogens are: 17 beta-estradiol (E-2), estrone and estriol, of which E-2 is the predominant and most active. The actions of E-2 are mediated by at least 3 different receptors - the classical ERs (ER alpha and ER beta) and G-protein coupled receptor 30 (GPR30). E-2 signaling in cardiomyocytes involves ER alpha- and ER beta-independent pathways, and treatment with the E-2 receptor antagonists (Selective Estrogen Receptor Modulators- SERMs), which are agonists of GPR30, inhibits cardiac cell growth. Effects of E-2 in preventing endothelial dysfunction, a prerequisite of atherosclerosis, are well recognized. Atherosclerosis involves interaction between the cells of the arterial wall endothelial cells (EC) and vascular smooth muscle cell (VSMC), as well as migration of macrophages into wall tunica media. It is predominantly developed at sites with abnormally high shear stress, such as bifurcations or branching of arteries, initiated by an injury to the endothelium and exposure to atherogenic lipids and toxins, such as those contained in tobacco smoke or infectious agents. Animal studies have shown effects of E-2 in preventing atherosclerosis, inflammation and endothelial or vascular dysfunction. Gender differences along this pathogenic pathway have been also described. We review the data from the available animal and human studies, which focus on anti-atherogenic effects of E-2. These studies represent evidence, albeit indirect, for an inhibitory effect of E-2 on the progression of coronary artery atherosclerosis.
T2  - Hormone and Metabolic Research
T1  - Anti-atherogenic Effects of 17 beta-Estradiol
VL  - 45
IS  - 10
SP  - 701
EP  - 708
DO  - 10.1055/s-0033-1343478
ER  - 

@article{
author = "Resanović, Ivana and Rizzo, Manfredi and Zafirović, Sonja and Bjelogrlic, P. and Perović, Milan and Savić, K. and Patti, A. M. and Isenović, Esma R.",
year = "2013",
abstract = "Estrogens are secreted primarily by the ovaries and placenta, by the testes in men and also produced by peripheral steroidogenic conversion. The 3 major naturally occurring estrogens are: 17 beta-estradiol (E-2), estrone and estriol, of which E-2 is the predominant and most active. The actions of E-2 are mediated by at least 3 different receptors - the classical ERs (ER alpha and ER beta) and G-protein coupled receptor 30 (GPR30). E-2 signaling in cardiomyocytes involves ER alpha- and ER beta-independent pathways, and treatment with the E-2 receptor antagonists (Selective Estrogen Receptor Modulators- SERMs), which are agonists of GPR30, inhibits cardiac cell growth. Effects of E-2 in preventing endothelial dysfunction, a prerequisite of atherosclerosis, are well recognized. Atherosclerosis involves interaction between the cells of the arterial wall endothelial cells (EC) and vascular smooth muscle cell (VSMC), as well as migration of macrophages into wall tunica media. It is predominantly developed at sites with abnormally high shear stress, such as bifurcations or branching of arteries, initiated by an injury to the endothelium and exposure to atherogenic lipids and toxins, such as those contained in tobacco smoke or infectious agents. Animal studies have shown effects of E-2 in preventing atherosclerosis, inflammation and endothelial or vascular dysfunction. Gender differences along this pathogenic pathway have been also described. We review the data from the available animal and human studies, which focus on anti-atherogenic effects of E-2. These studies represent evidence, albeit indirect, for an inhibitory effect of E-2 on the progression of coronary artery atherosclerosis.",
journal = "Hormone and Metabolic Research",
title = "Anti-atherogenic Effects of 17 beta-Estradiol",
volume = "45",
number = "10",
pages = "701-708",
doi = "10.1055/s-0033-1343478"
}

Resanović, I., Rizzo, M., Zafirović, S., Bjelogrlic, P., Perović, M., Savić, K., Patti, A. M.,& Isenović, E. R.. (2013). Anti-atherogenic Effects of 17 beta-Estradiol. in Hormone and Metabolic Research, 45(10), 701-708.
https://doi.org/10.1055/s-0033-1343478

Resanović I, Rizzo M, Zafirović S, Bjelogrlic P, Perović M, Savić K, Patti AM, Isenović ER. Anti-atherogenic Effects of 17 beta-Estradiol. in Hormone and Metabolic Research. 2013;45(10):701-708.
doi:10.1055/s-0033-1343478 .

Resanović, Ivana, Rizzo, Manfredi, Zafirović, Sonja, Bjelogrlic, P., Perović, Milan, Savić, K., Patti, A. M., Isenović, Esma R., "Anti-atherogenic Effects of 17 beta-Estradiol" in Hormone and Metabolic Research, 45, no. 10 (2013):701-708,
https://doi.org/10.1055/s-0033-1343478 . .